CHICAGO, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, will present at the J.P. Morgan Auto Conference on Tuesday, August 12th at 12:40 p.m. EDT. A simultaneous webcast can be accessed on the company’s website, www.methode.com, by selecting the Investors page. The webcast will also be archived on the same Investors page. About Methode Electronics, Inc.M ...

Q4 2025 Recurring & Other Revenue of $369.9 million, up 14% year-over-yearQ4 2025 Total Revenue of $400.7 million, up 12% year-over-yearFY 2025 Recurring & Other Revenue of $1,471.8 million, up 15% year-over-yearFY 2025 Total Revenue of $1,595.2 million, up 14% year-over-yearRepurchased 800,000 shares of common stock for $150 million during FY 2025Increased share repurchase authorization by $500 millionAnnounced the launch of Paylocity for Finance - expands the platform’s reach into the Office of the CFO, u ...

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2025. “We delivered an outstanding second quarter, achieving profitability in our MRD business with accelerating top- and bottom-line growth,” said Chad Robins, c ...

Core Insights - Treace Medical Concepts, Inc. announced positive four-year interim results from its ALIGN3D™ study, demonstrating the effectiveness of the Lapiplasty Procedure for bunion treatment [1][2][3] Company Overview - Treace Medical Concepts is focused on advancing surgical management standards for bunions and related midfoot deformities, with an estimated 1.1 million annual surgical candidates in the U.S. [5][6] - The company has developed the patented Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions by correcting deformities in three planes [6] Clinical Study Details - The ALIGN3D™ study is a multicenter, prospective clinical study evaluating the Lapiplasty Procedure's outcomes, with 173 patients enrolled across seven clinical sites [3] - Key findings from the study include: - Early return to protected weight-bearing at an average of 7.7 days and return to athletic shoes at 6.5 weeks [5] - Low radiographic recurrence rates of 0.8% for HVA>20° and 8.4% for HVA>15° at 48 months [5] - Significant improvements in pain and patient-reported outcomes, with an 81% improvement in pain and 89% improvement in walking/standing [5] Market Positioning - The publication of the ALIGN3D™ study results is expected to enhance the market differentiation of the Lapiplasty Procedure among surgeons and patients [2] - The company aims to expand its clinical evidence base and continue improving the standard of care for bunion surgery [2]

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company’s second quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/ve8zytc3/. A webcast repla ...

Core Viewpoint - DMC Global Inc. reported a decline in sales and adjusted EBITDA for the second quarter of 2025, reflecting challenging market conditions across its business segments, particularly in the architectural building products and energy sectors [1][2][3]. Financial Performance - Consolidated second-quarter sales totaled $155.5 million, a decline of 2% sequentially and 9% year-over-year [1][7]. - Adjusted EBITDA attributable to DMC was $13.5 million, down 6% sequentially and 30% compared to the same period last year, but above management's guidance [1][7]. - Net income attributable to DMC was $0.1 million, with adjusted net income of $2.5 million, or $0.12 per diluted share [7][20]. Segment Performance Arcadia (Architectural Building Products) - Sales were $62.0 million, down 5% sequentially and 11% year-over-year [2][9]. - Adjusted EBITDA was $4.0 million, down 28% sequentially and 46% year-over-year, primarily due to lower absorption of fixed manufacturing overhead [2][9]. DynaEnergetics (Energy Products) - Reported sales of $66.9 million, up 2% sequentially but down 12% year-over-year [3][10]. - Adjusted EBITDA was $9.0 million, up 22% sequentially and 3% year-over-year, attributed to lower material costs [3][10]. NobelClad (Composite Metals) - Sales were $26.6 million, down 5% sequentially but up 6% year-over-year [4][11]. - Adjusted EBITDA was $4.4 million, down 19% from the previous quarter and 23% from the year-ago period, mainly due to a less favorable order mix [4][11]. Guidance and Market Outlook - For the third quarter, sales are expected to be in the range of $142 million to $150 million, with adjusted EBITDA anticipated between $8 million and $12 million [6][19]. - The guidance reflects increased uncertainty in DMC's end markets, particularly in the U.S. construction industry and energy markets, influenced by macroeconomic concerns and tariff policies [6][19]. Debt and Financial Position - Total debt was reduced by 17% year-to-date, and the company amended its credit facility to enhance financial flexibility [5][7].

Core Insights - Terns Pharmaceuticals is advancing its clinical programs with a focus on oncology and obesity, expecting key clinical readouts by year-end 2025 [2][3] - The company has a strong cash position, with sufficient funds to support operations into 2028 [7][10] Clinical Trials and Pipeline Developments - The Phase 1 trial of TERN-701 for chronic myeloid leukemia (CML) is enrolling well, with efficacy and safety data, including 6-month major molecular response (MMR) rates, expected in Q4 2025 [1][3] - The Phase 2 trial of TERN-601 for obesity has completed enrollment, with 12-week efficacy, safety, and tolerability data anticipated in early Q4 2025 [1][8] - Terns plans to report data from the Phase 1 CARDINAL trial of TERN-701 in Q4 2025, which will allow for comparisons with other CML treatments [2][3] Financial Performance - As of June 30, 2025, Terns reported cash, cash equivalents, and marketable securities of $315.4 million, down from $358.2 million at the end of 2024 [7][10] - Research and development expenses for Q2 2025 were $20.4 million, compared to $18.4 million in Q2 2024 [7][9] - The net loss for Q2 2025 was $24.1 million, slightly higher than the $22.7 million loss in Q2 2024 [9] Corporate Updates - Terns will host an educational webinar focused on TERN-701 in September 2025 [1][3] - Members of Terns' senior leadership will participate in the Morgan Stanley 23 Annual Global Healthcare Conference in September 2025 [7]

Core Insights - Flywire Corporation reported a 27.2% year-over-year increase in revenue for the second quarter of 2025, reaching $131.9 million, compared to $103.7 million in the same quarter of 2024 [1][4] - The company reaffirmed its revenue guidance for fiscal year 2025 and raised its adjusted EBITDA margin guidance by 75 basis points at the midpoint [1][5] - The total payment volume increased by 22% to $5.9 billion in the second quarter of 2025, compared to $4.9 billion in the same quarter of 2024 [7] Financial Performance - Revenue less ancillary services increased by 27.7% to $127.5 million in the second quarter of 2025, compared to $99.9 million in the second quarter of 2024 [7] - Adjusted EBITDA rose to $16.6 million in the second quarter of 2025, compared to $5.8 million in the second quarter of 2024, with adjusted EBITDA margins increasing over 700 basis points year-over-year to 13% [7] - The net loss for the second quarter of 2025 was $12.0 million, an improvement from a net loss of $13.9 million in the second quarter of 2024 [4][7] Business Highlights - The company signed nearly 200 new clients across all verticals, excluding the added Sertifi properties and Invoiced software accounts [4] - Flywire was recognized by luxury travel network Virtuoso as a Technology Partner, gaining access to 2,300 preferred suppliers across 100 countries and $35 billion in annual luxury travel sales [4] - The company deepened its partnership with Ellucian, deploying new integrations to streamline implementations for educational institutions globally [4] Strategic Initiatives - Flywire signed a partnership with a leading provider of stablecoin payment infrastructure to integrate stablecoin payment capabilities into its global payment network [5] - The company has increased its revolving credit facility from $125 million to $300 million with improved terms, enhancing its liquidity position [7] - Flywire's share repurchase program has been increased by $150 million, bringing total authorization for future share repurchases to approximately $200 million [7] Guidance and Outlook - For fiscal year 2025, Flywire anticipates FX-neutral revenue less ancillary services growth of 17-23% year-over-year, with adjusted EBITDA margin growth of 200-350 basis points [6] - The company expects third-quarter FX-neutral revenue less ancillary services growth of 13-21% year-over-year [6]

Company Overview - Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS) [2] - The company's lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies [2] - Taysha aims to address severe unmet medical needs and improve the lives of patients and their caregivers through transformative medicines [2] Financial Results Announcement - Taysha Gene Therapies will report its financial results for the second quarter ended June 30, 2025, on August 12, 2025, at 8:30 AM Eastern Time [1] - A corporate update conference call and webcast will be hosted on the same date and time [1] Conference Call Details - The conference call will be held on Tuesday, August 12, at 8:30 AM Eastern Time / 7:30 AM Central Time [2] - Toll-free and international call-in numbers are provided for participants [2] - A webcast link is available for those who wish to join online [2]

Core Insights - Supernus Pharmaceuticals reported strong operating performance in Q2 2025, driven by significant sales growth of Qelbree and GOCOVRI, which together accounted for 72% of total net sales [2][5] - The company completed the acquisition of Sage Therapeutics on July 31, 2025, enhancing its portfolio in neuropsychiatric conditions with the innovative product ZURZUVAE and a novel CNS discovery platform [3][5] - Supernus is focused on the launch of ONAPGO and the integration of Sage Therapeutics while continuing to drive growth from existing products [2][3] Financial Performance - Qelbree net sales increased by 31% year-over-year to $77.6 million in Q2 2025, with total sales for the first half of 2025 reaching $142.3 million [5][11] - GOCOVRI net sales rose by 16% year-over-year to $36.7 million in Q2 2025, totaling $67.4 million for the first half of 2025 [5][11] - Total revenues for Q2 2025 were $165.5 million, a slight decrease from $168.3 million in Q2 2024, while total revenues for the first half of 2025 were $315.3 million, up from $312.0 million in the same period last year [11][12] Product Pipeline and Developments - The company is conducting a Phase 2b study for SPN-817, a novel AChE inhibitor for epilepsy, with a targeted enrollment of approximately 258 patients [7] - SPN-820, a novel molecule for depression, is set to enter a Phase 2b trial by the end of 2025, targeting around 200 adults with major depressive disorder [8] - SPN-443, a novel stimulant for ADHD/CNS, has completed a Phase 1 pharmacokinetic study, with plans to disclose a lead indication by the end of 2025 [9] Guidance and Future Outlook - Supernus updated its full-year 2025 revenue guidance to $670 - $700 million, reflecting strong first-half performance and the impact of the Sage acquisition [13][20] - The company anticipates combined R&D and SG&A expenses to be between $505 - $530 million for the year [13] - Adjusted operating earnings guidance for 2025 is projected to be between $105 - $135 million, consistent with previous expectations [13][37]